SCHEMBL14025560

SCHEMBL14025560

CN(Cc1ccccc1)S(=O)(=O)c1cccc(CNCc2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
HTT P42858 2/20 0.53
HPGD P15428 1/20 0.53
LMNA P02545 2/20 0.52
KDM4E B2RXH2 1/20 0.52
PKM P14618 1/20 0.52
MAPK1 P28482 1/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
ADRB2 P07550 1/20 0.51
MAPT P10636 1/20 0.51
HTR2C P28335 1/20 0.51
POLB P06746 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
NAMPT P43490 1/20 0.47
HSD17B1 P14061 1/20 0.47
HSD17B2 P37059 1/20 0.47
TAS2R14 Q9NYV8 1/20 0.47
NR1H3 Q13133 1/20 0.47
CXCR4 P61073 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14068043 0.88 MEN1 (0.44) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL14025548 0.87 PKM (0.53) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL14025633 0.84 ALDH1A1 (0.44) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL15676806 0.84 ALDH1A1 (0.57) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL14025567 0.83 HTT (0.53) ALDH1A1HTTLMNAKDM4EPOLB
SCHEMBL14025570 0.83 CASP3 (0.49) ALDH1A1HTTLMNAKDM4EMAPK1
SCHEMBL14025577 0.83 HTT (0.50) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL4745428 0.82 ALDH1A1 (0.56) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL14025574 0.82 TAAR1 (0.44) ALDH1A1HTTHPGDLMNAMEN1
SCHEMBL1696927 0.81 ALDH1A1 (0.54) ALDH1A1HTTHPGDLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
WO-2008109154-A1 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS, INC. (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A ALDH1A1 423/4885HTT 4443/4885HPGD 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.